FinTechFunding

Atalanta Therapeutics: Raises $110M in Series A Funding

  • Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding
  • The financing was provided exclusively by F-Prime Capital
  • Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group
  • As part of the strategic collaboration with Biogen, Atalanta will develop RNAi therapeutics for multiple targets
  • The company will be eligible to receive development and milestone payments on these programs as well as royalty payments on any resulting products
  • The strategic collaboration with Genentech involves the development of RNAi therapeutics for multiple CNS targets for neurodegenerative diseases
Previous article
Total Brain: Posts strong growth despite COVID-19 headaches
Next article
SpyGlass Ophthalmics: Closes $27.5M in Series B Financing
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Swedish Court Delays Judgment in Klarna’s Antitrust Case Against Google

The court's decision is crucial for Klarna's operations in the competitive market.Highlights: Swedish court delays decision on Klarna's...
FinTech

Morgan Stanley Launches Bitcoin ETF, Expanding Crypto Offerings

The investment firm broadens its reach into the cryptocurrency market.Highlights: Morgan Stanley launches a Bitcoin ETF to enhance...
FinTech

HSBC Strengthens Position with Hong Kong Stablecoin Issuer License

The banking giant aims to support digital asset initiatives in the region.Highlights: HSBC receives a stablecoin issuer license...
FinTech

US Treasury Secretary Warns Banks About Anthropic’s New AI Model

Treasury Secretary highlights risks AI poses to financial stability.Highlights: US Treasury Secretary warns banks about the risks of...